Boston Scientific has discontinued global sales of its Acurate neo2 and Acurate Prime transcatheter aortic valve replacement ...

Boston Scientific will eliminate jobs after discontinuing global sales of its Acurate aortic valve replacement systems that ...

Shares of Boston Scientific Corporation (BSX) traded 1% lower on Wednesday afternoon after the company announced that it is ...

Boston Scientific is pulling its latest transcatheter aortic heart valve platform from the worldwide market and said it will ...

Boston Scientific said it would halt worldwide sales of its Acurate devices due to “increased clinical and regulatory ...

Boston Scientific said it still expects to achieve its second-quarter and full-year 2025 sales and adjusted per-share earnings guidance despite the anticipated financial impacts from the ...

Edwards Lifesciences (EW) stock and Medtronic (MDT) stock gain as Boston Scientific (BSX) halts sales of ACURATE heart valves ...

According to the study’s abstract in The Lancet, TAVR with Acurate neo2 failed to meet non-inferiority. It also resulted in ...

The company also shared more details of its exit from the TAVR market and the impact of FDA layoffs on product review times.

Boston Scientific said on Wednesday it has discontinued sales of its heart device in the European Union and will not seek approval in the U.S. and other markets due to increased clinical and ...

The explanation for why the valve failed is too little, too late: Boston Scientific ended global sales of the device ...